Portia Ku


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.


Portia Ku is an accomplished corporate transactional lawyer who specializes in capital markets, mergers and acquisitions, venture capital and private equity financings. Portia’s clients include public and private companies that span a variety of industries, including the technology, life sciences, healthcare, and financial services sectors.

Portia has successfully completed a myriad of deals on behalf of her clients. She applies her expansive technical experience, strategic execution, and dedication to guide clients through highly complex transactions while ultimately helping them achieve their corporate goals.


  • Mandarin Chinese
  • Taiwanese

Honors & Awards

  • Recognized as a "Leading Lawyer" (2017)  and "Highly Regarded" (2018-2021) in Capital Markets and Private Equity by IFLR1000


Bar Admissions

  • California
  • New York
  • Hong Kong (Registered Foreign Lawyer)
  • Taiwan


  • Yale University, LL.M.
  • National Taiwan University, LL.B.

Professional Activities

Speaking Engagements

  • “Fundraising from the International Biotech Industry - Looking for Opportunities in Taiwan," Taiwan National Biotechnology Research Park (June 12, 2020)

Public and Private Offerings (companies):

  • Belite Bio, Inc (NASDAQ: BLTE) in its US$36 million IPO and listing on NASDAQ
  • Pharmaron in a Regulation S private offering of US$600 million of zero coupon convertible bonds due 2026
  • Pharmaron in its approximately US$588 million dual primary listing and H share offering in Hong Kong
  • eHi Car Services (NYSE: EHIC) in its US$120 million IPO and listing on the NYSE
  • Montage Technology Group Limited (NASDAQ: MONT) in its US$81.7 million IPO and listing on NASDAQ
  • China Kanghui Holdings (NYSE: KH) in its US$78.7 million IPO and listing on the NYSE
  • iSoftStone Holdings Ltd. (NYSE: ISS) in its US$162 million IPO and listing on the NYSE
  • 7 Days Group Holdings (NYSE: SVN) in its US$127.8 million IPO and listing on the NYSE
  • Giant Interactive Group Inc. (NYSE: GA) in its US$1.02 billion IPO and listing on the NYSE
  • WuXi PharmaTech (NYSE: WX) in its US$212 million IPO and listing on the NYSE
  • Acorn International, Inc. (NYSE: ATV) in its US$119.4 million IPO and listing on the NYSE
  • Mindray Medical International Limited (NYSE: MR) in its US$320 million IPO and listing on the NYSE
  • Christine International Holdings Ltd. (1210.HK) in its HK$400 million IPO and listing on the Hong Kong Stock Exchange
  • LifeTech Scientific Corporation (8122.HK) in its HK$283 million IPO on the Growth Enterprise Market of the Hong Kong Stock Exchange
  • Besunyen Holdings Company Limited (0926.HK) in its HK$1.3 billion IPO and listing on the Hong Kong Stock Exchange

Mergers & Acquisitions:

  • Dragonfly Energy Corp., an energy provider and battery producer, in its definitive business combination with a Nasdaq-listed SPAC company, which will make it a public company valued at US$500 million
  • Pharmaron in its US$118.7 million acquisition of Allergan Biologics Limited from AbbVie, Inc.
  • Pharmaron in its US$137.5 million acquisition of US-based Absorption Systems
  • Sundia Meditech Group in its US$80 million sale to a consortium led by Advent International Corporation
  • Pharmaron in its US$30 million seed round investment in AccuGen Group
  • BlueFocus/Blue Impact in the definitive share exchange agreement to be acquired by a SPAC listed on the NYSE
  • the three founders of Nanjing USA, Inc. in their trade sale to Roo Hsing Co., Ltd., a Taiwan listed company
  • eHi Car Services Co., Ltd. (NYSE: EHIC) in its US$937.5 million management buyout transaction
  • the two founders of Adicon Holdings Limited in a sale of 66% of the company to a consortium comprised of the Chinese-listed company Meinian Onehealth Healthcare, funds managed by the Caryle Group, and four Carlyle co-investors
  • Vivo Capital, in the consortium’s US$505 million acquisition of Angiotech Pharmaceuticals, Inc., a company specializing in the design and manufacturing of high performance surgical knives and wound closure products
  • Pharmaron, in its definitive agreement to acquire a majority stake in Shin Nippon Biomedical Laboratories Clinical Pharmacology Center, Inc. (SNBL CPC)
  • Pharmaron, in its definitive agreement with a consortium led by CITIC M&A Fund and Legend Capital, which will invest more than US$280 million in the company
  • Giant Interactive Group Inc. (NYSE: GA) in US$3 billion going private transaction
  • Xitogen Technologies in its sale to Danaher Corporation (NYSE: DHR)
  • China Hydroelectric Corporation (NYSE: CHC) in US$190 million buyout by controlling shareholder
  • China Kanghui in its US$816 million acquisition by Medtronic
  • LifeTech in a series of strategic investment transactions with Medtronic, including the sale of HK$2.18 billion of convertible notes to Medtronic
  • a shareholder group of China Hydroelectic Corporation in a cross-border proxy contest to remove a majority of the members of CHC’s board of directors and replace them with directors nominated by the shareholder group. The proxy contest culminated in the shareholder group’s proposals passing on all counts, followed by CHC and its management agreeing to settle on terms favorable to the shareholder group

Public and Private Offerings (underwriters):

  • Credit Suisse and Deutsche Bank in US$174 million US IPO of Tudou Holding Ltd. (NASDAQ: TUDO)
  • Morgan Stanley and CICC in US$132 million US IPO of Concord Medical Services Holdings (NYSE: CCM)
  • Credit Suisse and Citigroup in US$73 million US IPO of Chemspec International Limited (NYSE: CPC)
  • Merrill Lynch in US$108 million US IPO of China Sunergy Co., Ltd. (NASDAQ: CSUN)
  • the underwriters in the IPO of CNOOC
  • the underwriters in the IPO of Comtech
  • the underwriters in the IPO of TravelSky Technology
  • the underwriters in the IPO of Sohu.com

Business & Commercial Litigation:

  • JHL Biotech in achieving a favorable settlement over a biosimilars related trade secrets claim made by Genentech